지씨지놈
Financials
Valuation Metrics
지씨지놈's Market Cap is ₩2159B. Ranked #757 of 2,410 in KR market (top 31%), #335 of 1,631 on KOSDAQ (top 21%), #83 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 215.93B KRW | KR#757/2,410 Sec#83/231 |
| Revenue | 31.53B KRW | KR#2,010/2,410 Sec#139/231 |
| Net Income | 4.04B KRW | KR#1,279/2,410 Sec#90/231 |
| Total Assets | 84.63B KRW | KR#1,903/2,410 Sec#154/231 |
| Net Assets | 78.27B KRW | KR#1,606/2,410 Sec#131/231 |
| Value | ||
| P/E | 53.39x | KR#1,437/2,410 Sec#93/231 |
| P/B | 2.76x | KR#2,121/2,410 Sec#167/231 |
| P/S | 6.85x | KR#2,231/2,410 Sec#156/231 |
| EV/EBITDA | 146.34x | KR#1,515/2,410 Sec#103/231 |
| FCF Yield | 0.46% | KR#1,183/2,410 Sec#89/231 |
| Profitability | ||
| ROE | 5.17% | KR#1,080/2,410 Sec#74/231 |
| ROA | 4.78% | KR#765/2,410 Sec#61/231 |
| Op. Margin | 3.92% | KR#1,102/2,410 Sec#78/231 |
| Financial Health | ||
| Debt Ratio | 8.12% | KR#95/2,410 Sec#20/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | 985.6M KRW | KR#1,146/2,410 Sec#87/231 |
| Cash | 35.12B KRW | KR#910/2,410 Sec#60/231 |
| Current Ratio | 18.59x | KR#32/2,410 Sec#13/231 |
| Net Debt/EBITDA | -28.42x | KR#14/2,410 Sec#1/231 |
| Performance | ||
| 1Y Return | 28.23% | KR#253/2,410 Sec#13/231 |
| 1M Return | 2.82% | KR#178/2,410 Sec#16/231 |
| From 52W High | -12.88% | KR#63/2,410 Sec#2/231 |
| 1Y MDD | -53.71% | KR#1,120/2,410 Sec#91/231 |
| Trading | ||
| Volume | 633,889 shares | KR#34/2,410 Sec#2/231 |
| Trading Value | 5.80B KRW | KR#124/2,410 Sec#6/231 |
| Foreign Own. | 3.11% | KR#1,249/2,410 Sec#115/231 |
| Per Share | ||
| EPS | 171 KRW | KR#1,329/2,410 Sec#88/231 |
| BPS | 3,310 KRW | KR#1,802/2,410 Sec#137/231 |
Company Info
GC Genome, established in 2013, is a specialized clinical genomics analysis company that listed on KOSDAQ under special provisions for technology growth companies in 2025. It offers customized molecular diagnostic solutions covering the entire life cycle in four business areas, including obstetrics examinations, and supplies genomics services to domestic tertiary general hospitals and clinics. The company is expanding its domestic and international business, including entering the United States and Thailand, strengthening service quality through technology advancement, and diversifying its product portfolio. GC Genome is headquartered in Yongin-si, Gyeonggi-do.